Bryan Gervais de Liyis

Dr. Bryan Gervais de Liyis

Department of Neurosurgery, National Brain Center Hospital Mahar Mardjono, Jakarta, Indonesia
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2023 in The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
Verified
Journal Article
Open access
PDF file
JLJoshua Limantoro
Joshua Limantoro
Bryan Gervais de LiyisBryan Gervais de Liyis
Bryan Gervais de Liyis
JSJane Carissa Sutedja
Jane Carissa Sutedja
Alzheimer’s disease (AD) is a form of dementia marked by the accumulation of neuritic plaques and neurofibrillary tangles through the action of GSK-3β with both significant epidemiological and clinical impact. Current pharmacological treatment approaches are focused on symptomatic relief and aims to suppress AD’s progression rather than disease modification. This issue has triggered further investigations about tau pathology as an important component in AD’s pathophysiology, one of them being the Akt signaling pathway. Based on the problem served by AD, combined with the non-existence of conclusive therapy for this disease; hence, this study strives to further investigate the potential therapeutical benefit of Akt signaling towards AD. A total of 82 studies are included, consisting of both national and international articles creating a narrative review based on the PRISMA checklist. Variables searched on this study, include Alzheimer’s disease (AD), Akt signaling, serine-9 phosphorylation, and GSK-3β. Tau protein accumulation has been a mainstay in the physiopathology of AD, which are largely influenced by the GSK-3β expression. Akt signaling has been shown to inactivate GSK-3β through serine-9 phosphorylation. Thus, modulating and optimizing the Akt signaling pathway present encouraging prospects for the development of innovative and efficacious therapeutic strategies in addressing AD. Several studies have tried to estimate the harm and benefit as well as dose–effect relationship between Akt signaling and AD, concluding a promising beneficial effect for AD therapy. Here, we show the beneficial therapeutic effects of Akt signaling towards AD through both theoretical and empirical standpoints.

27 November 2023 in BioMedicine
Verified
Journal Article
Open access
PDF file
Bryan Gervais de LiyisBryan Gervais de Liyis
Bryan Gervais de Liyis
ACAngela Faustine Ciaves
Angela Faustine Ciaves
MIMarwa Humaira Intizam
Marwa Humaira Intizam
PJPierre Joshua Jusuf
Pierre Joshua Jusuf
IAI Made Junior Rina Artha
I Made Junior Rina Artha
Background: Assessing high-risk mortality in acute coronary syndrome (ACS) patients, encompassing ST-Elevation Myocardial Infarction (STEMI), Non-ST-Elevation Myocardial Infarction (NSTEMI), and Unstable Angina Pectoris (UAP), is crucial. However, the prognostic significance of hematological parameters in predicting high-risk mortality in ACS patients remains uncertain despite advancements in ACS research. Aim: The aim was to investigate prognostic significance of hematological parameters troponin, Creatine Kinase-MB (CKMB), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), Monocyte-to-Lymphocyte Ratio (MLR), Basophil-to-Lymphocyte Ratio (BLR), and Eosinophil-to-Lymphocyte Ratio (ELR) levels in predicting high-risk mortality in ACS patients. Methods: In this retrospective observational study, data from medical records of 115 patients with ACS, including 40 with STEMI, 38 with NSTEMI, and 37 with UAP, were analyzed. Patients were selected using stratified random sampling, whereby five patients were randomly chosen each month from January 2021 to December 2022 while maintaining a 1:1:1 ratio of selection. Results: Troponin (r=0.519) and NLR (r=0.484) showed moderate positive correlations with high-risk STEMI mortality. Meanwhile, troponin (r=0.387), NLR (r=0.279), PLR (r=0.276), MLR (r=0.250), BLR (r=0.237), and ELR (r=-0.344) were found to be significantly correlated with high-risk ACS mortality. Troponin, CKMB, NLR, and MLR were significant (AUC>0.7) for high-risk STEMI mortality, and Troponin, NLR, and MLR were significant for high-risk ACS mortality. The results of the multivariate regression analysis indicated that only Troponin (OR:2.049; 95%CI: 1.802 – 8.218; p=0.014), NLR (OR:1.652; 95%CI: 1.306 – 7.753; p=0.030), and MLR (OR:4.067; 95%CI: 1.182 – 13.987; p =0.026) were capable of predicting high-risk ACS mortality. Sub-group analysis showed an increased risk of ACS mortality by GRACE score >140 in patients with elevated levels of Troponin (OR:2.787; 95%CI: 1.032 – 7.524; p

27 May 2024 in World Neurosurgery
Verified
Journal Article
Closed access
Bryan Gervais de LiyisBryan Gervais de Liyis
Bryan Gervais de Liyis
GAGede Yudha Baskara Ardhaputra
Gede Yudha Baskara Ardhaputra
SLSulaiman Liyis
Sulaiman Liyis
DWDesak Made Wihandani
Desak Made Wihandani
YSYusak Mangara Tua Siahaan
Yusak Mangara Tua Siahaan
KPKomang Januartha Putra Pinatih
Komang Januartha Putra Pinatih

26 May 2022 in BioMedicine
Verified
Journal Article
Open access
PDF file
Bryan Gervais de LiyisBryan Gervais de Liyis
Bryan Gervais de Liyis
JNJohn Nolan
John Nolan
MMMade Agus Maharjana
Made Agus Maharjana
Osteoarthritis (OA) is a joint condition that causes significant impairment of the chondrocyte. The gradual degradation of the cartilage lining of one or more freely moving joints, as well as persistent inflammation, are the causes of osteoarthritis. Current medication focus on alleviating symptoms rather than curing the condition. The aim of this review is to evaluate the potential use of fibroblast growth factor receptor 1 extracellular vesicle as novel therapy for osteoarthritis. This review article was completed by searching for the keywords “Fibroblast Growth Factor Receptor 1”, “Extracellular Vesicle”, and “Osteoarthritis” in various journals in several search engines. Of the 102 scientific articles found, 95 were found suitable to be used as material in the making of this article. The upregulated amount of FGFR1 (fibroblast growth factor receptors) signaling suggesting the progression of degenerative cartilage that commonly seen in osteoarthritis (OA) patients. Several studies showed that the involvement of extracellular vesicles (EV) derived from MSCs could enhance cartilage repair and protect the cartilage from degradation. EVs have the potential to deliver effects to specific cell types through ligand-receptor interactions and several pathway mechanisms related with the FGFR1. EVs and FGFR1 have been postulated in recent years as possible therapeutic targets in human articular cartilage. The protective benefits on both chondrocytes and synoviocytes in OA patients can be achieved by administering the MSC-EVs that may also stimulate chondrocyte proliferation and migration EVs have a promising potential to become a novel therapy for treating patients with OA. However, further researches are need to be conducted to discover further the application of this therapy.

25 November 2023 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
Bryan Gervais de LiyisBryan Gervais de Liyis
Bryan Gervais de Liyis
SSStevanus Christian Surya
Stevanus Christian Surya
KTKumara Tini
Kumara Tini

10 June 2024 in The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
Verified
Journal Article
Open access
PDF file
KSKomang Trisna Sumadewi
Komang Trisna Sumadewi
Bryan Gervais de LiyisBryan Gervais de Liyis
Bryan Gervais de Liyis
NLNi Made Linawati
Ni Made Linawati
IWI Putu Eka Widyadharma
I Putu Eka Widyadharma
IAI Nyoman Mantik Astawa
I Nyoman Mantik Astawa
Background: Epilepsy initiation involves multifactorial etiologies, including genetic susceptibility, structural anomalies, and glial cell dysregulations, particularly in astrocytes. Despite advancements in understanding various factors, the mechanisms of astrocyte dysregulation in epilepsy, critical for neural homeostasis, remain elusive, requiring comprehensive evaluation of molecular pathways and cellular interactions for future targeted interventions. Methods: A systematic search of PubMed, ScienceDirect, and the Cochrane databases up to January 1st 2024 identified relevant studies predominantly from experimental models, forming the basis for an in-depth analysis of astrocytic contributions to epileptic pathophysiology. The aims, subjects, epilepsy induction techniques, assessment methods, and findings of each studies were presented. Results: A total of 24 clinical trials met the inclusion criteria and were included in the systematic review. Altered potassium buffering compromises extracellular potassium regulation, fostering hyperexcitability. Aquaporin dysfunction disrupts water homeostasis, aggravating seizure susceptibility. Disturbances in glutamatergic transmission, marked by changes in glutamate transporter function, contribute to excitotoxicity, fueling epileptogenesis. Intricacies in calcium signaling and disruptions in calcium-binding proteins tip intracellular calcium balance towards hyperexcitability. Dysfunctional GABA transporters compromise inhibitory neurotransmission, upsetting excitatory–inhibitory balance. Gap junction protein dysregulation disrupts astroglial networks, impacting neuronal synchronization in epileptogenic circuitry. Compromised BBB allows entry of epileptogenic factors, exacerbating the epileptogenic milieu. Conclusions: Collectively, these astrocytic dysregulations unveil intricate contributors to epilepsy onset and progression.